Guggenheim Downgrades Centessa Pharmaceuticals to Neutral

Centessa Pharmaceuticals

Centessa Pharmaceuticals

CNTA

0.00

Guggenheim analyst Debjit Chattopadhyay downgrades Centessa Pharmaceuticals (NASDAQ: CNTA) from Buy to Neutral.